Skip to Content
MilliporeSigma
All Photos(3)

Key Documents

View All Documentation

P6402

Sigma-Aldrich

Perphenazine

Perphenazine

Synonym(s):

4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol

Sign Into View Organizational & Contract Pricing

Select a Size

1 G
$94.80
5 G
$183.00

$94.80

In StockDetails

Request a Bulk Order
All Photos(3)

Select a Size

Change View
1 G
$94.80
5 G
$183.00

About This Item

Empirical Formula (Hill Notation):
C21H26ClN3OS
CAS Number:
58-39-9
Molecular Weight:
403.97
EC Number:
200-381-5
MDL number:
MFCD00056798
UNSPSC Code:
12352200
PubChem Substance ID:
24278642
NACRES:
NA.77

$94.80

In StockDetails

Request a Bulk Order

form

powder

Quality Level

200

originator

Schering Plough

storage temp.

2-8°C

SMILES string

ClC(C=C1)=CC2=C1SC3=CC=CC=C3N2CCCN4CCN(CCO)CC4

InChI

1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2

Inchi Key

RGCVKNLCSQQDEP-UHFFFAOYSA-N

Gene Information

human ... ADRA1A(148) , ADRA1B(147) , ADRA1D(146) , ADRA2A(150) , ADRA2B(151) , ADRA2C(152) , DRD2(1813) , OPRS1(10280)

Looking for similar products? Visit Product Comparison Guide

General description

Perphenazine is an antipsychotic drug used in treating schizophrenia.[1] It modulates antioxidant levels and helps in the management of oxidative injury in schizophrenia. However, it is less effective than the clozapine drug group in improving response to oxidative injury.[2]

Biochem/physiol Actions

D2 dopamine receptor antagonist; α-adrenergic receptor antagonist and σ-receptor agonist; phenothiazine antipsychotic. Inhibits glutamate dehydrogenase in vitro.

Features and Benefits

This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302,H317

Hazard Classifications

Acute Tox. 4 Oral - Skin Sens. 1

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCP4160
MKCN2541
MKCL7843
MKCJ3437
MKCG6835

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Chlorpromazine hydrochloride ≥98% (TLC)

Sigma-Aldrich

C8138

Chlorpromazine hydrochloride

J Nordenberg et al.
Biochemical pharmacology, 58(8), 1229-1236 (1999-09-16)
Some of the psychotropic agents widely used for the amelioration of anxiety, depression, and psychosis also show an effect at the cellular proliferation level. Surprisingly little research, however, has been directed to the antitumoral potential of these drugs, alone or
Donald E Addington et al.
The Journal of clinical psychiatry, 72(1), 75-80 (2010-09-28)
According to the American Psychiatric Association Clinical Practice Guidelines for schizophrenia, second-generation antipsychotics may be specifically indicated for the treatment of depression in schizophrenia. We examined the impact of these medications on symptoms of depression using the data from the
Angela M Koranek et al.
Schizophrenia research, 137(1-3), 137-140 (2012-03-01)
Results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) indicate that, with the exception of olanzapine, no substantial overall differences were identified between second generation antipsychotics (SGAs) and the first generation antipsychotic (FGA) perphenazine. This study evaluated the effect
Frank B Yoon et al.
Statistics in medicine, 30(16), 1917-1932 (2011-05-04)
In clinical trials multiple outcomes are often used to assess treatment interventions. This paper presents an evaluation of likelihood-based methods for jointly testing treatment effects in clinical trials with multiple continuous outcomes. Specifically, we compare the power of joint tests
Stanley N Caroff et al.
The Journal of clinical psychiatry, 72(3), 295-303 (2010-09-08)
We compared the response to antipsychotic treatment between patients with and without tardive dyskinesia (TD) and examined the course of TD. This analysis compared 200 patients with DSM-IV-defined schizophrenia and TD and 997 patients without TD, all of whom were
View All Related Papers

Articles

Glutamine Metabolism in Cancer Cells

Sigma article discusses tumor cell metabolic pathways, focusing on aerobic glycolysis and mitochondrial activity.

1 Review This action will navigate to reviews.

Questions

Reviews

Active Filters

  1. 1 Ratings-Only Review

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service